In SLE, the most commonly targeted antigen is CD19, expressed throughout B-cell development, including at low levels on early and some short-lived plasma cells but largely absent on long-lived bone-marrow plasma cells [27]. The gene discussed is CD19; the disease is systemic lupus erythematosus.